Nkarta, Inc. (NKTX)

NASDAQ: NKTX · IEX Real-Time Price · USD
8.59
+0.22 (2.63%)
At close: Dec 2, 2022 4:00 PM
9.65
+1.06 (12.34%)
Pre-market: Dec 5, 2022 5:34 AM EST
2.63%
Market Cap 408.57M
Revenue (ttm) n/a
Net Income (ttm) -104.07M
Shares Out 48.63M
EPS (ttm) -2.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 551,107
Open 8.27
Previous Close 8.37
Day's Range 8.02 - 8.64
52-Week Range 7.55 - 20.35
Beta 0.13
Analysts Buy
Price Target 32.45 (+277.8%)
Earnings Date Nov 9, 2022

About NKTX

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic synd... [Read more]

Industry Biotechnology
IPO Date Jul 10, 2020
Employees 146
Stock Exchange NASDAQ
Ticker Symbol NKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for NKTX stock is "Buy." The 12-month stock price forecast is 32.45, which is an increase of 277.76% from the latest price.

Price Target
$32.45
(277.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program

Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET

2 days ago - GlobeNewsWire

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

3 weeks ago - GlobeNewsWire

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale M...

Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models

3 weeks ago - GlobeNewsWire

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an...

1 month ago - GlobeNewsWire

7 Unknown Biotech Stocks That Could Rocket in 2023

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

2 months ago - InvestorPlace

Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

3 months ago - GlobeNewsWire

Should You Buy Nkarta (NKTX) Ahead of Earnings?

Nkarta (NKTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 months ago - Zacks Investment Research

Nkarta Announces Key Senior Leadership Team Appointments

SOUTH SAN FRANCISCO, Calif. , July 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ...

4 months ago - GlobeNewsWire

Trial Results Set to Make or Break Small-Cap Pharma Stocks

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration...

4 months ago - GuruFocus

Nkarta Stock a Bargain Compared to Fate Therapeutics

Investors who like Fate Therapeutics Inc. ( FATE , Financial) should love Nkarta Inc. ( NKTX , Financial).

Other symbols: FATE
5 months ago - GuruFocus

Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know

The consensus price target hints at a 209.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estim...

5 months ago - Zacks Investment Research

Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today ann...

6 months ago - GlobeNewsWire

What Makes Nkarta, Inc. (NKTX) a New Buy Stock

Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 383.4% in Nkarta, Inc. (NKTX). While the effectiveness of this highly sought-after metric is questionable, the po...

6 months ago - Zacks Investment Research

Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ca...

6 months ago - GlobeNewsWire

Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ca...

6 months ago - GlobeNewsWire

2 Red-Hot Stocks That Soared More Than 60% in April

Could these be the next big meme stocks?

6 months ago - The Motley Fool

Positive Clinical Results Put Nkarta Stock on the Fast Track

NKTX stock is a fast mover, and a recent share-price bump came in the wake of exciting data from a "killer cell" anti-cancer research program. The post Positive Clinical Results Put Nkarta Stock on the ...

6 months ago - InvestorPlace

Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purc...

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announ...

7 months ago - GlobeNewsWire

Up 131% in a Day, Is This Hot Stock a Buy?

Some of its early clinical data look much better than expected.

7 months ago - The Motley Fool

Nkarta Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announ...

7 months ago - GlobeNewsWire

Nkarta Scores Huge Gain on Cancer Treatment Results

Bargain hunters may want to feast their eyes on a South San Francisco-based biotech focusing on cancer treatments.

7 months ago - GuruFocus

Nkarta Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announ...

7 months ago - GlobeNewsWire

Here is why Nkarta is 40% up

Nkarta Inc. (NASDAQ: NKTX) is up 40% after announcing positive preliminary Phase 1 findings from its dose-finding trials of NKX101 and NKX019 in hematological malignancies. NKX101 and NKX019 are two lea...

7 months ago - Invezz

Why Is Nkarta (NKTX) Stock Soaring 90% Today?

Nkarta (NKTX) stock is rocketing higher on Monday after the company released preliminary data from a Phase 1 clinical trial. The post Why Is Nkarta (NKTX) Stock Soaring 90% Today?

7 months ago - InvestorPlace